At Least 6 Deaths Potentially Linked To Abortion Drug

Seven deaths were detailed in the records released to Judicial Watch, but one of those deaths may have been reported twice.

The records were made public as a result of an October 2022 Judicial Watch Freedom of Information Act lawsuit that was filed after the FDA failed to respond to three February 2022 requests for records, including correspondence with the manufacturers of Mifeprex, regarding the drug's stability, and for all FDA reports from assessments of DANCO and GenBio manufacturing facilities; investigational and new drug applications, as well as stability test results.

The records made public include an "Annual Report for Mifepristone," covering the period September 28, 2000, to September 27, 2001, produced by the Population Council/Danco Laboratories, LLC. The summary indicates that during the testing period, 32 "Adverse events were reported to Danco and reported by Danco to FDA in periodic reports."

Of the 32 reported adverse events, two were 15-day reports.

One of the 15-day reports was reported as "Hemorrhage due to a ruptured ectopic pregnancy and death." The other was reported as "Post abortal parametritis/endometritis, adult respiratory distress syndrome and bilateral pneumonia." This latter 15-day report and one case where fever was reported represent the total reports on the marketed drug suggesting infection.

A post-marketing study dated September 28, 2001, titled "Comparison of abortions induced by mifepristone followed by vaginal versus oral misoprostol up to 56 days gestation," reports on the "Safety results" for 940 women.

A September 27, 2002, report on mifepristone indicates that in a study of 971 women administered a combination of mifepristone and misoprostol to induce abortions, one subject needed a blood transfusion, two were administered IV fluids, one was hospitalized, and one died.

https://sharylattkisson.com/2023/10/read-at-least-6-deaths-potentially-linked-to-abortion-drug/